Calamos Advisors LLC Takes $281,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

Calamos Advisors LLC bought a new position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,694 shares of the company's stock, valued at approximately $281,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Artisan Partners Limited Partnership boosted its position in Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company's stock worth $137,241,000 after buying an additional 1,961,621 shares during the period. Nikko Asset Management Americas Inc. increased its position in Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company's stock valued at $131,835,000 after purchasing an additional 99,511 shares during the period. Dimensional Fund Advisors LP raised its holdings in Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company's stock worth $46,732,000 after purchasing an additional 284,884 shares during the last quarter. Baillie Gifford & Co. raised its holdings in Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock worth $42,116,000 after purchasing an additional 132,770 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Twist Bioscience by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company's stock worth $16,522,000 after purchasing an additional 5,728 shares during the last quarter.

Twist Bioscience Trading Up 2.6 %

NASDAQ TWST traded up $1.14 during mid-day trading on Tuesday, hitting $45.12. The company's stock had a trading volume of 619,998 shares, compared to its average volume of 1,022,006. The company's 50 day simple moving average is $49.37 and its 200 day simple moving average is $42.56. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of -13.43 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same period in the previous year, the business posted ($1.01) EPS. The business's revenue for the quarter was up 27.7% compared to the same quarter last year. As a group, research analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a "buy" rating and a $53.00 price target for the company. Evercore ISI raised their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, May 3rd. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a report on Monday, August 5th. Finally, TD Cowen lifted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $48.22.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $47,120.94. Following the transaction, the senior vice president now directly owns 90,593 shares of the company's stock, valued at approximately $4,650,138.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Twist Bioscience news, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $47,120.94. Following the transaction, the senior vice president now directly owns 90,593 shares of the company's stock, valued at approximately $4,650,138.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,408 shares of Twist Bioscience stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $123,602.64. Following the transaction, the chief executive officer now directly owns 507,578 shares in the company, valued at $26,053,978.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,327 shares of company stock valued at $978,760. 3.92% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.